Five-year disease-free survival among stage II-IV breast cancer patients receiving FAC and AC chemotherapy in phase II clinical trials of Panagen

Table 5 Five-year overall survival for stage III breast cancer

	Chemotherapy + Placebo				Chemotherapy + Panagen				[25]	[24]
	Patients	Survived patients	%		Patients	Survived patients	%		Survival, %	Survival, %
IIIA	2	1	50	50	7	7	100	79	57	66.7
IIIB	6	3	50	50	12	8	67	79	57	41
IIIC	0	-		-	6	6		100
Stage III, total	8	4		50	25	21		84

ISSN: 1471-2407